Abstract
Adjuvant chemotherapy of postmenopausal axillary node-positive women with breast carcinoma in 1977 suggested a disease-free survival benefit but no overall survival benefit with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) [1]. In advanced disease the subsequently reported results with CMF + prednisone (CMFP) were superior to CMF [2] and the addition of tamoxifen to a chemotherapy regimen appeared to enhance effectiveness [3]. Accordingly, in 1977 the Eastern Cooperative Oncology Group (ECOG) designed an adjuvant trial for axillary node-positive postmenopausal patients to compare observation with 1 year of postoperative therapy with CMFP of CMFP + tamoxifen (CMFPT). The current results from this trial are presented.
For the Eastern Cooperative Oncology Group
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, DeLena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410
Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Cancer 50: 1235–1244
Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE (1982) Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Cancer Clin Trials 5: 33–39
Tormey DC, Weinberg VE, Holland JF, Weiss RB, Glidewell OJ, Perloff M, Falkson G, Falkson HC, Henry PH, Leone LA, Rafla S, Ginsberg SJ, Silver RT, Blom J, Carey RW, Schein PS, Lesnick GJ (1983) A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer — a cancer and leukemia group B study. J Clin Oncol 1: 138–145
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
Tormey D, Fisher B, Bonadonna G, Carter S, Davis H, Glidewell O, Hahn RG, Payne S, Zelen M, Sears ME (1977) Proposed guidelines. In: Carbone PP, Sears ME (eds) Report from the Combined Modality Trials Working Group in Breast Cancer: suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. DHEW, Washington (DHEW publication no. [NIH] 77–1192, pp 20–35 )
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 135: 185–198
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc [B] 34: 187–220
Lehman EL (1975) Nonparametrics: Statistical methods based on ranks. Holden Day, San Francisco
Fisher RA (1934) Statistical methods for research workers. University Press, Edinburgh
Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669–4671
Hähnel R, Woodings T, Vivian AB (1979) Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675
Bertuzzi A, Daidone MG, DiFronzo G, Silvestrini R (1981) Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Res Treat 1: 253–261
Ernst P, Killmann S-A (1970) Perturbation of generation cycle of human leukemic blast cells by cytostatic therapy in vivo: effect of corticosteroids. Blood 36: 689–696
Osborne CK, Blodt DH, Clark GM, Trent JM (1983) Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583–3585
Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J, Fisher ER (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227–241
Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodses RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL (1981) Adjuvant therapy of stage II breast cancer. Breast Cancer Res Treat 1: 77–82
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Tormey, D.C., Taylor, S.G., Gray, R., Olson, J.E. (1984). Postmenopausal Node-Positive Comparison of Observation with CMFP and CMPF + Tamoxifen Adjuvant Therapy: An Eastern Cooperative Oncology Group Trial. In: Senn, HJ. (eds) Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82357-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-82357-2_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82359-6
Online ISBN: 978-3-642-82357-2
eBook Packages: Springer Book Archive